Bristol-Myers Squibb Co vs McCormick & Company, Incorporated — how do they compare? Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B), while McCormick & Company, Incorporated trades at $52.73 (market cap $14.22B). The key difference: Bristol-Myers Squibb Co is far larger — about 9.1× McCormick & Company, Incorporated's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | MKC | |
|---|---|---|
Market Cap | $129.94B | $14.22B |
Sector | Health | Consumer Staples |
52-Week High | $65.89 | $72.26 |
52-Week Low | $42.60 | $45.60 |
Enterprise Value | $163.92B | $18.82B |
Dividend Yield | 3.96% | 3.63% |
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →